[Home]
[Full version]
Researchers discover one of the mechanisms that prevents the spread of colon cancer
Sep 30 ,Medicine & Health
The first step in the development of colon cancer is the formation of benign tumours, called adenomas, in the intestine. Over time, these tumours may progress to produce colon cancer if they undergo a series of mutations and genetic alterations.
Researchers at IRB Barcelona under the direction of Eduard Batlle, ICREA researcher and head of IRB Barcelona’s Oncology Programme, have discovered a new mechanism by which the benign tumour cells receive instructions to grow in confined compartments, and no to invade other areas of the tissue. The description of this new tumour suppression mechanism is reported in the scientific journal Nature Genetics.
The scientists observed that adenomatous tumour cells have special surface receptors, called EphB2 and EphB3, which detect the presence of certain ligands in the healthy tissue that surround them. These receptors and their ligands serve to organize the structure of intestinal tissue. Thanks to the activity of EphB2 and EphB3, the tumour cells are forced to “listen to” the signals that they receive from their environment. These signals make the benign tumours grow in a confined space, from which they are unable to spread. “We knew that these receptors worked as tumour suppressors, but we did not know how. Now we have been able to observe that they compartmentalize the tumour, thereby preventing its spread”, explains Batlle.
Until the tumour cells learn to deactivate these receptors, they cannot invade other tissue outside the compartment. Batlle goes on to say, “as the tumour cells progress to become malignant, their genetic programme is refined and they remove the signals that block their growth, including these two receptors, which impose positional information”.
This study explains one of the key mechanisms of how a benign tumour transforms into a malignant one during the onset of colon cancer. Using experiments performed with animal models and in vitro cells, the scientists determined that the loss of compartmentalization, that is to say, the loss-of-function of these two receptors, is one of the vital factors in the development of adenoma-derived colon cancer.
It is estimated that between 30 and 50% of people over 60 years of age may develop one of these benign adenomas. Cancer of the colon ranks first in the list of the most common cancers in Spain, with more than 25,000 causes diagnosed each year. Last year alone, more than half a million people worldwide died as a result of this disease.
Source: Institute for Research in Biomedicine
Related stories:
New type of drug shrinks primary breast cancer tumors significantly in just 6 weeks
A drug that targets the cell surface receptors that play an important role in many types of cancer can bring about significant tumour regression in breast cancer after only six weeks of use, a scientist told the 6th European Breast Cancer Conference (EBCC-6) today. Dr. Angel Rodriguez, from the Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, USA, said that the work demonstrated for the first time that the tyrosine kinase inhibitor lapatinib could decrease tumour-causing breast cancer stem cells in the primary breast cancers of women receiving neoadjuvant treatment (treatment given before the primary surgery for the disease).
HSP90: New point of view on melanoma of the eye
Ocular melanoma is rarely detected before it has grown large enough to impair vision or to metastasize. This makes it a particularly challenging disease to fight, especially since chemotherapy is not very effective.
Researchers discover 'instruction manual' that tells cancers how to hide from immune system
A mechanism that creates an “invisibility cloak” for certain cancer cells and allows them to hide from the immune system has been uncovered by a team of researchers at the University of British Columbia.
How adhesive protein causes malaria
Researchers at the Swedish medical university Karolinska Institutet (KI) and the Swedish Institute for Infectious Disease Control (SMI) have identified the biochemical mechanism behind the adhesive protein that give rise to particularly serious malaria in children. The knowledge of how the malaria parasite makes blood vessels become sticky paves the way for a future vaccine for the disease, which currently kills some 2 million people every year.
Blocking beta1-integrin to treat cancer
Targeting the function of a protein known as beta1-integrin might represent a novel approach to cancer treatment, according to a paper published online in The EMBO Journal this week. Blocking the action of this protein could help to prevent the formation of metastases by reducing tumour cell proliferation and inducing cell senescence.
Important mechanism identified in the formation of blood vessels
All tissues, sick and healthy alike, need a blood supply to survive and grow. The key to many medical problems, like preventing tumour development, is therefore to obstruct the spread of the blood vessels. Research scientists at Karolinska Institutet have now discovered a heretofore unknown mechanism for how the body links together its blood vessels.
Surprise discovery made in cancer research
One of the defining characteristics of cancer cells is that they systematically prevent programmed cell death (apoptosis), with which the body guards itself against the proliferation of defective cells. In order to do this, they express so-called apoptosis inhibitors (IAPs) among other proteins.
Immune cells reveal fancy footwork
Our immune system plays an essential role in protecting us from diseases, but how does it do this exactly? Dutch biologist Suzanne van Helden discovered that before dendritic cells move to the lymph nodes they lose their sticky feet. This helps them to move much faster. Immature dendritic cells patrol the tissues in search of antigens. After exposure to such antigens they undergo a rigorous maturation process. During this maturation the dendritic cells migrate to the lymph nodes to activate T cells. Suzanne van Helden studied the adhesion and migration of both immature and mature dendritic cells.
[Home]
[Full version]